Stop worrying; start growing: Risk research on GM crops is a dead parrot: it is time to start reaping the benefits of GM by Fagerström, Torbjörn et al.
©2012 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION  EMBO reports  VOL 13 | NO 6 | 2012 493
science & society science & society
E
ver since the Asilomar Conference on 
‘Recombinant DNA’ in February 1975, 
regulatory policies relating to recom-
binant DNA technology have focused on 
the idea that this technology implies threats 
to human health and the environment [1]. 
As a consequence, the explicit goal of these 
policies is to protect society and nature 
from an assumed hazard, or, if protection 
is not possible, at least to delay the imple-
mentation of the technology until scientific 
evidence shows it to be harmless. These pol-
icies were widely accepted at the time, as 
public concerns were, and still are, impor-
tant. As time has gone by, the evidence for 
negative impacts of genetically modified 
(GM) crops has become weaker. However, 
the regulatory policies within the EU are 
still rigid enough to prevent most GM crops 
from leaving the confined laboratory set-
ting; should some candidate occasionally 
overcome the hurdles posed by these poli-
cies, the precautionary principle is invoked 
in order to ensure further delaying in its use 
in the field. The reason for this over-cautious 
approach is widespread public resistance to 
GM crops, caused and amplified by inter-
ested groups that are opposed to the tech-
nology and invest heavily into lobbying 
against it.
Against this background of political 
resistance, it is no surprise that the risks, 
costs and potential disadvantages of not 
growing GM crops have received little or 
no attention. These disadvantages become 
increasingly relevant as the scientific argu-
ments for the prevailing resistance to GM 
crops become weaker. Twenty-five years of 
risk research on GM crops have established 
beyond reasonable doubt that biotechnol-
ogy is not per se riskier than conventional 
plant breeding technologies [2]. The whole 
seemingly endless discussion about pur-
ported risks of GM crops is akin to the 
famous Monty Python sketch in which John 
Cleese is trying to return a dead parrot to 
shopkeeper Michael Palin, who, despite the 
evidence, insists that the bird is well, alive 
and “pining for the fjords”. Instead, we need 
to highlight the opportunities missed by not 
accepting GM crops. These include lost rev-
enues for farmers, breeding companies and 
consumers, brain drain and lost technology 
innovations, reduced agricultural product-
ivity and sustainability, foregone health ben-
efits, especially reducing malnutrition, and 
many more realized or expected virtues of 
GM crops [3]. 
R
isk assessment and risk analysis of 
genetically modified organisms 
(GMOs) is governed by interna-
tionally accepted guidelines, developed 
by the Codex Alimentarius Commission 
(www.fao.org). One leading principle is 
the concept of substantial equivalence, 
which stipulates that any new GM variety 
should be assessed for its safety by compar-
ing it with an equivalent, conventionally 
bred variety that has an established his-
tory of safe use [4]. Despite the fact that the 
Codex Alimentarius guidelines are glob-
ally endorsed, the authorization procedure 
for GMOs differs substantially between 
national juris  dictions. Europe stands out 
as being considerably more restrictive 
than countries in North and South America 
and parts of Asia, for example. Within the 
European Union (EU), a common regula-
tory legal framework such as Regulation 
(EC) No. 1829/2003, governs GM crops 
intended for human food and animal feed. 
Any party seeking approval for an edible 
GM crop must provide extensive scientific 
documentation that demonstrates that the 
food or feed derived thereof has no adverse 
effects on human and animal health or the 
environment, does not mislead the con-
sumer, or does not differ from the food it is 
intended to replace to such an extent that its 
normal consumption would be nutritionally  
disadvantageous for the consumer.
The risk assessment is conducted and 
compiled by the applicant, and is evalu-
ated by the GMO Panel of the European 
Food Safety Authority (EFSA). The opinion 
of the panel should form the scientific basis 
when member states provide other legiti-
mate arguments and cast their votes in the 
Standing Committee for Food and Animal 
Health of the European Commission. 
Thus, the decision to approve a particular 
GMO should be on the basis of scientific 
grounds. By the same logic, one might take 
for granted that only GMOs that have been 
shown to have adverse effects on animal or 
human health or the environment will not 
receive approval. In practice, however, the 
decision whether or not to approve a par-
ticular GMO is not solely a scientific issue. 
Several member states vote, in principle, 
against approval, irrespective of the sci-
entific opinion delivered by the EFSA [5]. 
In recognition of this dead-lock, the 
European Commission (EC) has suggested 
that individual member states should have 
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the right to restrict cultivation of a given 
GM crop even if there are no scientifically 
established risks, that is, to adopt restric-
tions on the basis of socio-economical or 
ethical grounds [6].
In addition to the scientific documenta-
tion provided by the applicants who seek 
approval of a GM crop, public research 
has investigated the risks of GMOs during 
the past 15 years. The Directorate-General 
Research under the EC has spent €200 
million during the past decade on such 
research, and several member states have 
initiated national research programmes 
specifically targeting the potential impact 
of the very same crops and traits that are in 
the European approval system [2]. A col-
laborative working group under the Standing 
Committee on Agricultural Research (SCAR) 
has estimated that the funds allocated 
to national risk research on GMOs in 13 
European countries amount to at least 
€120 million during the past eight  years 
(http://bmg.gv.at/home/Schwerpunkte/
Gentechnik/Fachinformation_Allgemeines/
SCAR_Collaborative_Working_Group 
_Risk_Research_on_GMOs).
I
n a report from 2010, the EC summarized 
the results of 130 research projects involv-
ing more than 500 independent research 
groups and concluded that biotechnology 
is not per se riskier than conventional plant 
breeding technologies [2]. Further support for 
this position comes from the UK Farm-Scale 
Evaluation (FSE), which studied the potential 
impact of herbicide-tolerant crops on farm-
land biodiversity [7]. One insight from the 
study is that overall changes in agricultural 
management determine the impact of a crop 
on biodiversity, rather than the technology   
or breeding behind the crop itself [8].
Between 2008 and 2009, the EFSA GMO 
panel evaluated a renewal to permit the con-
tinued import, processing and culti  vation 
of maize variety MON810 for food and 
feed. MON810 expresses the Cry1Ab pro-
tein from the soil-borne bacterium Bacillus 
thuringiensis   (Bt), which confers resistance 
to the European corn borer, and is one of 
two GM crops approved for cultivation in 
Europe; it was first approved in 1998. As a 
basis for its 2009 opinion, the EFSA GMO 
Panel summarized 48 peer-reviewed papers 
on the potential risks of MON810 on animal 
and human health and the environment, in 
addition to the documentation provided by 
the company [9]. It found no adverse effects 
and concluded that MON810 is compar-
able with its conventionally bred parental 
lines. The only difference reported was that 
MON810 has an increased variability in 
lignin content, in some studies it has been 
found to be higher and in some studies lower. 
Similarly, a review by Icoz & Stotzky [10] 
of studies on the effects of insect-resistant 
Bt crops on soil ecosystems found no 
notable detrimental effects on microbes 
and other organisms in below-ground 
soil ecosystems. Accordingly, the authors   
concluded that “…available funding would 
be better spent on studies of the potential 
risks associated with the release of trans-
genic plants genetically engineered to 
express pharmaceutical and industrial prod-
ucts that, in contrast to Cry proteins, are tar-
geted primarily to human beings and other 
higher eukaryotic organisms.”
I
f, as 15 years of intense research and risk 
assessment have shown, GM crops do not 
pose greater risks for human health or the 
environment than conventionally bred varie-
ties, it is time to look at the other side of the 
equation and gauge the possible benefits of 
adopting and growing GM crops. To that end, 
Fagerström & Wibe [11] analysed the poten-
tial economic consequences for Sweden of 
farmers not growing GM crops—herbicide-
tolerant sugar beet and canola, and late 
blight-resistant potato—and then extended 
the analysis to all of the EU. They considered 
two rough categories of impact: effects that 
could be evaluated by studying market prices 
that show impacts for producers on work-
force and capital, and demand for fertilizers, 
pesticides and fuel, and factors related to the 
cost of keeping GM crops separated from 
conventionally or organically grown crops 
during cultivation, harvest, transport, storage 
and processing. The latter cost arises from the 
European attitude of regarding GM crops and 
products as contaminants—as if we were 
dealing with toxic substances.
In 2008, Sweden produced almost 
2 million tons of sugar beet grown on 
approximately 37,000 hectares and with 
a production value of €70 million. The 
authors calculated that a shift to herbicide- 
tolerant sugar beet could have led to a 
5–10% increase in yield. Expenditure 
on seeds would increase from €180 to 
€210 per hectare, but the cost of herbicides 
would decrease from €180 to €55. Taken 
together, the cost of input goods would 
decrease by 27%.
Analysis of the sugar beet shows that 
the economic value to producers and, by 
extension,   to society is strategically depend-
ent on two factors: the cost of keeping GM 
sugar separate from conventional sugar, and 
the public acceptance of GM sugar. The cru-
cial limit was found to be a separation cost of 
25% of the price; at this limit, the economic 
value to society vanishes even if all consum-
ers buy GM products—if public acceptance 
is 100%. In a realistic scenario the separa-
tion cost is ~10% of the price and the public 
acceptance is ~25% of the consumers. Thus, 
the economic benefit would be €1.3 mil-
lion, or ~2% of the total value of sugar beet 
production. If GM crops enjoyed full public 
acceptance, and if there were accordingly 
no costs of separation, the economic gain   
to society would amount to €10 million; 
about 14% of the total value of sugar beet 
production. Approximately 3,000 hectares 
of arable land—8% of the acreage of sugar 
beet—would be available for other uses.
Similar values apply for potato and can-
ola, so introducing these three GM crops in 
Sweden would yield an economic value of 
€30 million annually. In addition, producers 
would regain 10,000 hectares (ha) of ara-
ble land; using official statistics on leasing 
costs for arable land in Sweden, this has an 
annual value of approximately €2 million. 
This adds up to a combined annual value 
to society of €32 million. The accumulated 
value of this annual revenue over many 
years—the so-called capitalized value—is 
€1–€1.6 billion at an interest rate of 2–3%. 
The annual gain amounts to approximately 
14, 11 and 5% of the production value for 
sugar beet, canola and potato, respectively. 
EU-wide, a shift to these three GM crops 
would yield a gain of ~€2 billion annually, 
and would save ~645,000 ha, which corre-
sponds to a capitalized value in the range of 
€80–€120 billion.
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T
hese calculations presuppose full 
public acceptance of GM crops; that 
is, a world in which consumers per-
ceive GM crops as equal to or better than 
non-GM varieties. In addition, the results 
rest on the assumption that the benefits to 
the environment such as decreased use of 
pesticides can be measured by the cost of 
the pesticides. Presumably, this is an under-
estimate of the environmental benefits, 
and the societal value is therefore probably 
greater than the figures presented above.
Other studies address the problem of 
missed economic benefits, often using 
economic models similar to those used by 
Fagerström & Wibe [11]. Generally, they 
confirm the results discussed above: the 
magnitudes of the unrealized benefits are 
similar. Matin Qaim, an agricultural econ-
omist at Göttingen University, Germany, 
for example, presented figures for Bt cot-
ton adoption that would entail global wel-
fare gains in the range of €0.5–€1.0 billion 
per year [12]. The biggest impact occurs in 
China, but India, where the relevant tech-
nology was more recently commercialized, 
has been catching up rapidly. It is estimated 
that the widespread adoption of Bt cotton in 
India and other countries of South Asia will 
result in further regional welfare gains on 
the order of €1 billion per year.
The benefits of adopting GM oilseeds 
and maize are amplified by the larger inter-
national markets on which they are traded. 
While the annual global welfare gains at the 
present moderate level of adoption are esti-
mated at €3.5 billion [13], this figure could 
reach approximately €7.5 billion with wide-
spread international adoption of herbicide-
tolerance and insect-resistant crops [12]. 
However, it is also noted that a ban on pro-
duction and imports by the EU could reduce 
these global gains by two-thirds owing to 
unrealized benefits for domestic consumers 
and the far-reaching influence of EU policies 
on international trade flows and production 
decisions in other regions.
Large global welfare gains are projected 
for GM rice as well. Assuming that there 
is moderate adoption of GM rice in rice-
producing regions, the combined global 
welfare gains are estimated to be in the 
region of €5 billion per year for Bt-carrying, 
herbicide-resistant and drought-tolerant 
rice varieties, with India and China gaining 
the most. Projected welfare gains in China 
alone could reach more than €3 billion 
when first-generation GM rice technologies 
are widely adopted. Both studies [11,12] 
highlight that available analyses probably 
provide lower estimates of the global wel-
fare effects of GM crops, because other 
environmental and health benefits have not 
been properly quantified.
A
griculture is blamed frequently for 
biodiversity loss. Several recent stud-
ies, however, demonstrate that the 
design of the agricultural landscape, with 
refuges for non-crop species, intercrop-
ping and crop rotation, can counter  balance 
the effects of an intensified agriculture sys-
tem [14]. Hence, one of the most important 
consequences of better yields from herbi-
cide and pest-resistant GM crops in Europe 
would be that the surplus land could be 
used for refuges to promote biodiversity 
in the farming landscape and save natural 
forests from deforestation or wetlands from 
being drained to make way for farmland. 
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distances, as well as other measures to keep 
GM crops separate from conventionally 
bred varieties, lock GM crops into large-
scale agricultural practices and, in effect, 
prevent intercropping. Thus, the principle of 
non-coexistence limits the scope for farmers 
to take full advantage of the benefits of pre-
sent and future GM crops to further reduce 
the need for pesticides and increase the 
productivity of farmland. This line of rea-
soning is supported by a recent study show-
ing that the willingness of farmers to adopt 
GM crops is substantially hampered by 
the costs and uncertainties associated with 
co  existence regulations, despite lower costs 
for chemicals [15].
H
istorically, cereal crop varieties have 
been replaced by new varieties on 
average every 5–10 years [16]. The 
reasons for this turnover vary, but one under-
lying drive for crop replacement is the rapid 
loss of resistance traits. In order to maintain 
yield levels, farmers must either increase 
their use of chemicals to kill pests, or change 
to a new crop variety; hence the continu-
ous breeding for resistance traits. Imminent 
climate changes will put further constraints 
on agricultural production, including an 
increasing need for faster and more effi-
cient plant breeding to adapt crops to more 
variable local conditions [17]. If breeders 
fail in this regard, agro-chemical use will 
increase and Europe will become more 
dependent on imports. In Europe, the spatial 
variation in rainfall is expected to increase: 
Northern Europe can expect a more humid 
climate, which will constrain crop produc-
tion owing to the increased severity of biotic 
stresses such as insect pests, fungal patho-
gens and the invasion of alien, noxious spe-
cies, whereas crop production in southern 
Europe will have to be adapted to drier con-
ditions [18,19]. Thus, not adopting modern 
breeding tools—including biotechnology—
will probably hamper the European agri-
cultural systems facing a warmer and more 
variable climate [20].
Legislation that determines what consti-
tutes a GMO was ratified in 2001. In a legal 
sense, a GMO is defined as an organism in 
which the genetic material has been altered 
in a way that does not occur naturally by 
mating or natural recombination, and refers 
to both plants and animals, except humans. 
In practice, a GMO is defined by an adden-
dum to the Directive 2001/18EC, which 
lists the techniques that give rise to a GMO. 
Since the Directive 2001/18EC was ratified, 
ten years have passed, and technology has 
progressed further. Many of the techniques 
listed in the addendum have been improved 
or are obsolete. A recent report to the EC 
by the Joint Research Centre [21] describes 
new methods, their possible applications for 
plant breeding and potential implications 
for agriculture. One common aspect of the 
new techniques is that many involve the use 
of recombinant DNA or RNA molecules in 
one phase of the breeding process; however, 
these recombinant molecules are not pre-
sent in the final product and are commonly 
not transmitted to the next generation.
Interestingly, European scientists at 
public and private institutions are at the 
forefront of technological development 
concerning new breeding. In this respect 
the situation is similar to the history of plant 
transformation technologies first devel-
oped at European universities [22], but 
now mainly used outside Europe [23]. By 
way of illustration, BASF, the company that 
developed the Amflora potato, announced 
recently that it is halting research on GM 
crops in Europe. Ultimately, the develop-
ment and success of scientific know-how 
and new technology in Europe, as well 
as the adoption of new techniques and 
crops, will depend on the decisions made 
by European legislators who are discussing 
GM technologies and their ratification.
As a comparison, other genetically 
engineered products, such as biopharma-
ceuticals, are approved for humans and 
food-producing animals after ordinary 
science-based safety assessments [23], 
without the ideological stigmatization and 
biased decision-making processes seen for 
GM crops.
O
ur review of the state-of-affairs of 
GM crops in Europe raises several 
fundamental issues. First, the bur-
den of EU legislation for GM technologies 
is completely out of proportion compared 
with other science-based endeavours. 
This is manifested by the substantially 
longer time required for a GM product to 
reach approval within the European legal 
framework (45 months), compared with 
GMO-exporting countries such as the 
USA, Canada or Brazil (27 months) [24]. 
In addition, these European approval times 
are only valid for importing commodities; 
approvals for cultivation in Europe take 
substantially longer. It took 14  years for 
the Amflora potato, for example, which is 
only the second GM crop to be approved in 
Europe. Not only are rules more restrictive 
in Europe, but only the largest companies in 
the seed and plant breeding business have 
the financial capacity to go through the 
lengthy and costly procedure required for 
approving a GM crop variety. This hampers 
small and medium business and prevents 
business spin-offs from plant research.
Second, research priorities in regard to 
the environmental impacts of agriculture 
are not directed in a productive way; risk 
research in Europe is not helping to develop 
sustainable agriculture for the future. The 
paradigm that stipulates that bio  technology 
is inherently risky, and singles out one plant 
breeding technology as the basis for risk 
research, is putting a massive regulatory bur-
den on a technology that could enhance sus-
tainability. As a consequence, any future risk 
research on GMOs in Europe should address 
the costs of this burden and the risks of not 
using biotechnology. We conclude that the 
research programmes set up in the EU to 
address the potential risks of GM crops are 
no longer scientifically motivated inquiries. 
The scientific community has already settled 
the relevant questions regarding potential 
risks associated with GM crops approved 
under legislation; what is going on is a politi-
cal game. In this game, the so-called precau-
tionary principle is used, in absurdum, to 
delay any launch of a GM crop far beyond 
the limit of reasonable scientific doubts.
Third, it is time to acknowledge the dis-
tinct imbalance with respect to the costs 
and benefits of GM crops: lobbyists who 
benefit from demonizing GM crops are 
not the ones who have to carry the costs. 
Hence, it is not the hyped risks of GM crops 
that are a problem in the EU, it is the sub-
missive attitude of politicians and policy-
makers towards organizations who insist 
that GM crops are risky. It is then ordinary 
consumers who pay the costs and do not 
receive the benefits. This submissiveness 
manifests in the prevailing policy that GM 
products should be kept separate from non-
GM products, as well as the incessant calls 
for regulations about labelling and tracea-
bility. As shown above, the potential benefit 
to the European economy from adopting 
GM crops is substantial. But these potential 
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of the ACCELERATES project. Environ Sci Pol 
9: 93–100
19.  Garrett KA et al (2011) Complexity in climate-
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effects mediated by plant disease. Plant Pathol 
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917–924
25.  Nowicki P et al (2010) Study on the 
Implications of Asynchronous GMO 
Approvals for EU Imports of Animal Feed 
Products. Wageningen, the Netherlands: 
European Commission
benefits vanish altogether when the costs 
of maintaining separation and consumer 
resistance are brought into play as a result 
of misinformation campaigns.
Risk research on GM crops in Europe has 
to come to an end, as do futile battles about 
disasters that will not happen. A dead par-
rot is a dead parrot, both in Monty Python 
sketches and in science. The way to sustain-
able and productive agriculture is not by 
maintaining expensive, parallel production 
systems, using different sets of crop varie-
ties, and relying on expensive regulations 
for their coexistence. Instead, agricultural 
systems should use the best available tech-
nology at all stages, including plant breed-
ing. It is clear that the approval and decision 
process within the EU for GM crops is not 
science-based. The risk assessment and 
approval process, where the outcome is 
dominated by the opinions of a few self-
interested stakeholder organizations with 
special interests is unique. It is alarming that 
decision-making bodies kow‑tow to this 
non-science-based paradigm.
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